[go: up one dir, main page]

NO995065L - Indole derivatives with combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity - Google Patents

Indole derivatives with combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity

Info

Publication number
NO995065L
NO995065L NO995065A NO995065A NO995065L NO 995065 L NO995065 L NO 995065L NO 995065 A NO995065 A NO 995065A NO 995065 A NO995065 A NO 995065A NO 995065 L NO995065 L NO 995065L
Authority
NO
Norway
Prior art keywords
alkyl
nitrogen
oxygen
sulfur
hydrogen
Prior art date
Application number
NO995065A
Other languages
Norwegian (no)
Other versions
NO995065D0 (en
Inventor
Laramie Mary Gaster
Harshad Kantilal Rami
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9707829.9A external-priority patent/GB9707829D0/en
Priority claimed from GBGB9801882.3A external-priority patent/GB9801882D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO995065L publication Critical patent/NO995065L/en
Publication of NO995065D0 publication Critical patent/NO995065D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med formel(l), fremgangsmåter for deres fremstilling og anvendelse av dem som CNS-midler er beskrevet: hvor Ra er en gruppe med formel (i) hvor P1 er fenyl, bicyklisk aryl, en 5- til 7-leddet heterocyklisk ring inneholdende 1 til 3 heteroatomer valgt fra oksygen, nitrogen og svovel eller en bicyklisk, heterocyklisk ring inneholdende 1 til 3 heteroatomer valgt fra oksygen, nitrogen og svovel; R1 er hydrogen, halogen, C-j^alkyl. Cs.øcykloalkyl, COCi^alkyl, C-i.galkoksy, hydroksy, hydroksyCi.ealkyl, hydroksyC-i-ealkoksy, Ci_6alkoksyCi_6alkoksy, C-|_6alkanoyl, nitro, trifluormetyl, cyano, SR9, SOR9, SO2R9. SO2NR10R11, CO2R10, CONR1°R11, C02NR10R11, (CH2)cNR10R11. (CH2)CCONR1°R11, 6alkyl, CO2(CH2)COR10, NR10R11, NR1°CO2R11, NR10CONR10R11, CR1°=NOR11, NR10COOR11, CNR1°=NOR11. hvor R10 og R11 uavhengig er hydrogen eller C-j.salkyl og c er 1 til 4 R2 er hydrogen, halogen, C^alkyl, Cs.ecykloalkyl, Cs.gcykloalkenyl, C-i.galkoksy, acyl, aryl, acyloksy, hydroksy, nitro, trinuormetyl, cyano, CO2R10PCONR1 OR! 1, NR1°R11 hvor R10 og R11 er som definert for R1; aerl, 2 eller 3; eller Ra er en gruppe med formel (ii) (ii) hvor P2 og P3 uavhengig er fenyl, bicyklisk aryl, en 5- til 7- leddet heterocyklisk ring inneholdende 1 til 3 heteroatomer valgt fra oksygen, nitrogen og svovel eller en bicyklisk heterocyklisk gruppe inneholdende 1 til 3 heteroatomer valgt fra oksygen, nitrogen eller svovel; A er en binding eller oksygen, S (O)m hvor m er O til 2, karbonyl, CH2 eller NR4 hvor R4 er hydrogen eller C-i-øalkyl; R1 er som definert ovenfor for formel (l) eller R"! er en eventuelt substituert 5- til 7-leddet heterocyklisk ring inneholdende 1 til 3 heteroatomer valgt fra oksygen, nitrogen eller svovel; R2 og R3 er uavhengig hydrogen, halogen, C-i-salkyl, Cs.øcykloalkyl, C3_6cykloalkenyl, C^alkoksy, acyl, aryl, acyloksy, hydroksy, nitro, trifluormetyl, cyano, CO2R10, CONR10R11, NR10R11 hvor R10 og R11 er som definert for R1; og a og b er uavhengig 1, 2 eller 3; Y er - NH -, NR$ hvor R5 er C-|_6alkyl eller Y er - CH2 - eller - O -; V er oksygen eller svovel; D er nitrogen, karbon eller en CH gruppe; Wer (CR16R17)t hvor t er 2, 3 eller 4 og R16 og R17 er uavhengig hydrogen eller Ci^alkyl eller Wer (CR16R17)U-J hvor u er O, 1, 2 eller 3 og J er oksygen, svovel, CR16=CR17, CR16=N, =CR16Q, =CR16S eller =CR16-NR17; X er nitrogen eller karbon; Rb er hydrogen, halogen, hydroksy, Ci-galkyl, trifluormetyl, C-^alkoksy, C2- salkenyl, Cs.ycykloalkyl eventuelt substituert med C^alkyl eller aryl; Rc er hydrogen eller Ci_salkyl; og ¿ er en enkeltbinding når X er nitrogen eller en enkelt- eller dobbeltbinding når X er karbon.Compounds of formula (I), processes for their preparation and use of them as CNS agents are described: wherein Ra is a group of formula (i) wherein P1 is phenyl, bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur; R 1 is hydrogen, halogen, C 1-6 alkyl. C 1-6 cycloalkyl, CO C 1-6 alkyl, C 1-6 alkoxy, hydroxy, hydroxyC 1-6 alkyl, hydroxyC 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkoxy, C 1-6 alkanoyl, nitro, trifluoromethyl, cyano, SR9, SOR9, SO2R9. SO2NR10R11, CO2R10, CONR1 ° R11, CO2NR10R11, (CH2) cNR10R11. (CH2) CCONR1 ° R11, 6alkyl, CO2 (CH2) COR10, NR10R11, NR1 ° CO2R11, NR10CONR10R11, CR1 ° = NOR11, NR10COOR11, CNR1 ° = NOR11. wherein R 10 and R 11 are independently hydrogen or C 1-6 alkyl and c is 1 to 4 R2 is hydrogen, halogen, C 1-6 alkyl, C 6 -cycloalkyl, C 6 , cyano, CO2R10PCONR1 OR! 1, NR1 ° R11 wherein R10 and R11 are as defined for R1; aerl, 2 or 3; or Ra is a group of formula (ii) (ii) wherein P2 and P3 are independently phenyl, bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur or a bicyclic heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur; A is a bond or oxygen, S (O) m where m is 0 to 2, carbonyl, CH 2 or NR 4 where R 4 is hydrogen or C 1-6 alkyl; R 1 is as defined above for formula (I) or R 1 is an optionally substituted 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur; R 2 and R 3 are independently hydrogen, halogen, C alkyl, C 6 cycloalkyl, C 3-6 cycloalkenyl, C 1-4 alkoxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO2R10, CONR10R11, NR10R11 where R10 and R11 are as defined for R1 and a and b are independently 1 or 3; Y is - NH -, NR $ where R 5 is C 1-6 alkyl or Y is - CH 2 - or - O -; V is oxygen or sulfur; D is nitrogen, carbon or a CH group; Wer (CR16R17) t where t is 2, 3 or 4 and R16 and R17 are independently hydrogen or C1-4 alkyl or Wer (CR16R17) UJ where u is O, 1, 2 or 3 and J is oxygen, sulfur, CR16 = CR17, CR16 = N, = CR16Q, = CR16S or = CR16-NR17; X is nitrogen or carbon; Rb is hydrogen, halogen, hydroxy, C1-6 alkyl, trifluoromethyl, C1-6 alkoxy, C2-salkenyl, C1- cycloalkyl optionally substituted with C1-6 alkyl or aryl; Rc is hydrogen or C1-6 alkyl; and ¿is a single bond when X is nitrogen or a single or double bond when X is carbon.

NO995065A 1997-04-18 1999-10-15 Indole derivatives with combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity NO995065D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9707829.9A GB9707829D0 (en) 1997-04-18 1997-04-18 Novel compounds
GBGB9801882.3A GB9801882D0 (en) 1998-01-29 1998-01-29 Novel compounds
PCT/EP1998/002262 WO1998050358A1 (en) 1997-04-18 1998-04-14 Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity

Publications (2)

Publication Number Publication Date
NO995065L true NO995065L (en) 1999-10-15
NO995065D0 NO995065D0 (en) 1999-10-15

Family

ID=26311401

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995065A NO995065D0 (en) 1997-04-18 1999-10-15 Indole derivatives with combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity

Country Status (17)

Country Link
EP (1) EP0975593A1 (en)
JP (1) JP2001524116A (en)
KR (1) KR20010006487A (en)
CN (1) CN1260781A (en)
AR (1) AR013076A1 (en)
AU (1) AU732863B2 (en)
BR (1) BR9809092A (en)
CA (1) CA2288662A1 (en)
CO (1) CO4950608A1 (en)
HU (1) HUP0001123A3 (en)
IL (1) IL132409A0 (en)
NO (1) NO995065D0 (en)
NZ (1) NZ500252A (en)
PL (1) PL336317A1 (en)
TR (1) TR199902590T2 (en)
TW (1) TW509687B (en)
WO (1) WO1998050358A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725931D0 (en) * 1997-12-05 1998-02-04 Smithkline Beecham Plc Novel compounds
AU753360B2 (en) 1998-07-31 2002-10-17 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
GB9827882D0 (en) * 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
JP2003505369A (en) * 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション Heterocyclic compounds for treating migraine
IL148818A0 (en) 1999-09-25 2002-09-12 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b
DE60017446T2 (en) * 1999-11-05 2006-03-02 Smithkline Beecham P.L.C., Brentford Isoquinoline and quinazoline derivatives with combined 5-HT1A, 5-HT1B and 5-HT1D receptor affinity
GB9926303D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
DE10051981A1 (en) 2000-10-20 2002-05-02 Bayer Ag Substituted phenyluracile
GB0106419D0 (en) 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
GB0106586D0 (en) * 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
DE60218037T2 (en) * 2001-06-07 2007-08-23 F. Hoffmann-La Roche Ag NEW INDOIND DERIVATIVES WITH AFFINITY TO THE 5-HT6 RECEPTOR
ATE416168T1 (en) * 2002-02-15 2008-12-15 Glaxo Group Ltd MODULATORS OF THE VANILLOID RECEPTOR
KR100636475B1 (en) 2002-05-13 2006-10-18 에프. 호프만-라 로슈 아게 Benzoxazine Derivatives and Uses thereof as 5-HT6 Modulators
JP4527730B2 (en) 2003-12-09 2010-08-18 エフ.ホフマン−ラ ロシュ アーゲー Benzoxazine derivatives and uses thereof
MX2010006046A (en) * 2007-12-13 2010-06-23 Amgen Inc Gamma secretase modulators.
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN102924330A (en) * 2012-09-03 2013-02-13 华东理工大学 Method for large-scale preparation of 5-amino-1-naphthyl nitrile
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN103467374A (en) * 2013-08-30 2013-12-25 江苏弘和药物研发有限公司 Synthesis method of 8-bromine-4-carboxyl quinoline
PL3083616T3 (en) 2013-12-20 2021-12-06 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
JP6693107B2 (en) * 2015-12-04 2020-05-13 東ソー株式会社 Method for purifying lutidine compound
CN115197099A (en) * 2022-05-30 2022-10-18 安徽昊帆生物有限公司 Preparation method of N-Boc-1,4-phenylenediamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
PT533268E (en) * 1991-09-18 2002-02-28 Glaxo Group Ltd BENZANILIDA DERIVATIVES AS 5-HT1D ANTAGONISTS
JPH09501171A (en) * 1993-08-06 1997-02-04 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Amide derivatives as 5HT1D receptor antagonists
JPH09504004A (en) * 1993-08-20 1997-04-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Amide and urea derivatives for 5HT1D receptor antagonists
DE69417427T2 (en) * 1993-09-03 1999-11-25 Smithkline Beecham P.L.C., Brentford INDOL AND INDOLIN DERIVATIVES AS 5HT1D RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
WO1998050358A1 (en) 1998-11-12
CO4950608A1 (en) 2000-09-01
EP0975593A1 (en) 2000-02-02
AU7431098A (en) 1998-11-27
AR013076A1 (en) 2000-12-13
KR20010006487A (en) 2001-01-26
CN1260781A (en) 2000-07-19
NO995065D0 (en) 1999-10-15
BR9809092A (en) 2002-01-22
TW509687B (en) 2002-11-11
HUP0001123A2 (en) 2001-04-28
IL132409A0 (en) 2001-03-19
AU732863B2 (en) 2001-05-03
PL336317A1 (en) 2000-06-19
CA2288662A1 (en) 1998-11-12
HUP0001123A3 (en) 2002-04-29
TR199902590T2 (en) 2000-06-21
JP2001524116A (en) 2001-11-27
NZ500252A (en) 2001-07-27

Similar Documents

Publication Publication Date Title
NO995065L (en) Indole derivatives with combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
WO1999042465A3 (en) Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
YU22996A (en) New derivatives of arylglycineamide, processes for their preparation and pharmaceutical preparations containing these compounds
DE69110320D1 (en) Heterocyclic compounds containing nitrogen, their preparation and use.
PT771794E (en) HETEROCYCLIC COMPOUNDS CONTAINING OXYGEN
DK0984966T3 (en) 9-azabicyclo [3.3.1] non-2-one derivatives which are cholinergic ligands on nicotine ACh receptors
DE69929689D1 (en) HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF HEART FAILURE AND OTHER DISEASES
CO4950609A1 (en) NEW COMPOUNDS
AR002011A1 (en) COMPOUNDS DERIVED FROM PIPERIDINE, ITS SALTS AND N-OXIDES, PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS.
NO982913L (en) Quinoline and quinazoline compounds useful in therapy
EE9700227A (en) Arylglycinamide derivatives, process for their preparation and pharmaceutical preparations containing these compounds
DK0622076T3 (en) Inhibitor of restenosis after percutaneous coronary arterioplasty
DK1034174T3 (en) Azaring ether derivatives and their use as nicotine ACh receptor modulators
ATE182889T1 (en) BICYCLIC AMIDEINE DERIVATIVES AS NO-SYNTHETASE INHIBITORS
DE69202120D1 (en) Urea derivatives, their production and their use in therapy.
EA200100090A2 (en) New piperide-4-sulphonamide compounds, a process for their preparation and pharmaceutical compositions containing them
ATE176231T1 (en) TRIAZINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
ATE199543T1 (en) BIBPHENYLAMIDE DERIVATIVES AS 5-HT1D ANTAGONISTS
NZ221699A (en) Pyridazinone derivatives; pharmaceutical compositions and intermediates
DE69810107D1 (en) AZACYCLOOKTAN AND HEPTAN DERIVATIVES, THEIR PRODUCTION AND THEIR THERAPEUTIC USE
ES486071A1 (en) Amine derivatives
EA199901050A2 (en) New imidazoline compounds, method of preparation thereof and pharmaceutical compositions comprising them
WO2000005224A3 (en) Heterocyclic derivatives and their use as integrin inhibitor
EA200400469A1 (en) SUBSTITUTED DERIVATIVES ALKYLAMINOPIRIDAZINONE, METHOD OF THEIR RECEIVING AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
DK0734384T3 (en) 3-substituted 1-arylindole compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application